Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The study will assess the efficacy and safety of SPARC1310 when compared to placebo and active control

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Pharma Advanced Research Company Limited

Criteria

Inclusion Criteria:

• Male or female participants aged 18 to 65 years with history of seasonal allergic rhinitis

• Participants able to understand and willing to sign the informed consent form

Exclusion Criteria:

• Anotomical deviations of the nasal septum that significantly impair ventilation or airflow

• Pregnant or nursing women

• Positive serology for infectious disease (Hepatitis B or C, HIV) at screening

• Parallel participation in another current investigational study, participation in a study within less than 30 days prior to study entry, or previous participation in this same study.